Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis, asthma, and CRSwNP as core indications. Learn ...

ARS Pharmaceuticals, Inc. reported 2025 revenues of $84.3m, a net loss of $171.3m, and plans to sustain high SG&A spending.

A string of FDA approvals and late-stage clinical trials has expanded the toolkit for treating seasonal and environmental allergies, giving patients new ways to manage symptoms and, in some cases, ...

Researchers conducted a matching-adjusted indirect comparison of phase 3 trials, using placebo as a common comparator, to evaluate the efficacy of omalizumab vs dupilumab in patients with CSU. They ...

Please provide your email address to receive an email when new articles are posted on . CU Index, serum IgE and blood histamine content were assessed. Patients with two bioindicators had greater odds ...

A combination of medications and lifestyle adjustments can help you manage chronic hives and ease your symptoms.

HealthDay News — Individuals with one to three allergenic foods are able to introduce and continue eating allergenic foods at 12 months after multifood oral immunotherapy (mOIT) or omalizumab, ...

PHILADELPHIA -- Most multi-food allergic children succeeded in longer term regular dietary consumption whether treated with oral immunotherapy (OIT) or omalizumab (Xolair) alone, results from stage 3 ...

Children with food allergy who used omalizumab plus oral immunotherapy vs. omalizumab alone had similar rates of allergen ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The lawsuit alleges the imported ...

Patients maintain their improvements off treatment, even after clearance of barzolvolimab, investigators report.